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specialized diagnostic arrays significantly improves the accuracy
of diagnosis of suspect masses in the pancreas. We have con-
structed diagnostic arrays to only contain genes with diagnostic
and/or prognostic potential for the classification of pancreatic
tissues, augmented with control features. Our results demon-
strate that this setup is suitable to produce reliable, reproducible
and informative expression profiles of pancreatic tissues and
biopsy samples. Expression profiling analysis using the special-
ized diagnostic array in conjunction with conventional cytology
allows the distinction between pancreatic ductal adenocarci-
noma (PDAC) and non-malignant diseases of the pancreas with
almost 100% diagnostic accuracy. We are currently in the process
of analyzing additional tumor entities, such as acinar and neu-
roendocrine tumors, using both the diagnostic array as well as
large scale arrays, in order to develop a multiclass classification
system for the comprehensive diagnosis of different malignan-
cies in the pancreas. In addition, we expect further development
of the array in combination with careful analysis of clinical
patient data to result in the recognition of distinct prognostic
gene expression signatures predicting important clinical param-
eters such as stage of disease, response to therapy, or prognosis.
Specialized DNA arrays thus represent valuable new diagnostic
tools which can significantly expand the range of information
gained in routine diagnostic procedures, thus providing a better
basis for decisions on treatment options and setting the stage
for therapeutic regimens custom tailored to the individual
patient.
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Trained neural networks can be used to construct scoring mod-
els for molecular staging in cancer. They offer considerable flex-
ibility for representing nonlinear interactions, but because of
their flexibility they also tend to require substantial ‘‘training’’
data. It often happens that clinical factors are available in a
large collective, but molecular data is available only for a smaller
subset. A hierarchical neural net training architecture is pre-
sented here. Hierarchical nets are trained in levels, the first level
on a large cohort with limited (usually clinical) factors, the sec-
ond and possibly higher levels on cohort subsets with more
(usually molecular) factors, and so on. The scores produced at
the first level are treated as ‘‘factors’’ for the second level, and
so on. In diseases with distinctly classifiable modes or sites of
recurrence (e.g., bone vs. soft tissue in breast cancer), the ‘‘com-
peting’’ risks can be modelled within the neural network archi-
tecture. To test the hypothesis that a molecular staging factor
might signal the particular relapse mode, one can study signifi-
cant correlations between factors and ‘‘hidden’’ nodes of a
trained neural network. A method is also described for using
trained neural nets to generate hypotheses about potential sub-
groups for molecular staging targets. Applications to breast,
colon, and gastric cancer are reviewed.
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In the Division of Functional Genome Analysis at DKFZ, we are devel-
oping technologies for the identification, description and evalua-
tion of cellular functions and their regulation by producing and
processing biological information on a genomic scale. Many
chemical and biophysical issues are being addressed in an
attempt to understand the underlying procedural aspects,
thereby establishing superior analysis processes.
Concerning human material, systems are being developed
toward early diagnosis, prognosis and evaluation of the success
of disease treatment with an accentuation on cancer. To this
end, comparative studies on epigenetic and splice variations,
transcription factor binding, transcriptional activity and actual
protein expression are under way. Early diagnosis from body flu-
ids is being worked at that is based on the binding of their com-
ponents to peptide and antibody microarrays.
Combining this data with clinical information permits the
definition of patient sub-groups and may provide a robust
means for diagnosis and prognosis and lead to the identification
of relevant molecular activities. We have established processes –
both experimentally and in the area of bioinformatics – to deal
with this challenge. The combination will not only occur in sil-
ico, since the various molecular levels affect each other exten-
sively. Soon, current in silico systems biology will translate
into ever more complex experimental set-ups that permit an
evaluation of a biological issue in a systemic experimentation.
Similar to research in physics, an iterative interaction of theoret-
ical and experimental systems biology will yield important
insights into function, providing the archetypal platform for an
eventual model of a cell.
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A plethora of computational methods for the diagnosis of can-
cer using gene expression profiling has been suggested. This
might come as a surprise, since diagnosis appears to be a
straightforward classification problem. What can be done with
methods from standard statistics textbooks? Clearly, the prob-
lem is the large number of genes on the arrays. Including them
all in a classification model leads to saturation of the model.
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